Moderna MRNA earnings Q3 2021


Moderna shares fell by more than 16% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.

The company said some doses for delivery this year have been shifted to early 2022 amid production issues and as it prioritizes deliveries to low-income countries through COVAX, the U.N.-backed effort to share coronavirus vaccines. It now expects Covid vaccine sales of between $15 billion and $18 billion this year, down from an earlier projection of $20 billion.

In releasing its third-quarter earnings, Moderna said it is now expecting to deliver between 700 million and 800 million doses this year, down from its…

Source cnbc.com

0 0 votes
Article Rating

Experts offer money advice college grads need to hear but never get

Previous article

Employment roars back in October as payrolls rise by 531,000

Next article

You may also like

Notify of
Inline Feedbacks
View all comments

More in Earnings